


Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

Claims 1 – 33 (cancelled)

34. (Currently amended) A compound having the formula Ia [[or Ib]];



P represents a [[5- or]] 6-membered heteroaromatic ring containing one or two ~~heteroatoms~~ selected independently from N, O and S of which at least one heteroatom is nitrogen;

R¹ is hydrogen;

R² is ~~selected from: C₁₋₆alkyl, cyano, halogen, (CO)OR¹⁰, and CONR¹⁰R¹¹;~~

R³ is selected from: C₁₋₆alkyl, cyano, nitro, (CO)OR⁴, C₁₋₆alkylNR⁴R⁵, OC₂₋₆alkylNR⁴R⁵, CONR⁴R⁵, SO₂R⁴, OSO₂R⁴ and (SO₂)NR⁴R⁵;

R⁴ is selected from: hydrogen, CF₃ and C₁₋₆alkyl;

~~R⁵ is selected from: hydrogen, C₁₋₆alkyl, C₁₋₆alkylNR⁶R⁷ and;~~ wherein R⁴ and R⁵ may together form a 4-, 5-, 6- or 7-membered heterocyclic group containing one or more heteroatoms selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;

~~R⁶ and R⁷ are independently selected from hydrogen, C₁₋₆alkyl, (CO)C₁₋₆alkyl, and wherein R⁶ and R⁷ may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S, wherein said heterocyclic group may optionally be substituted by a group Y;~~

R^8 and R^9 are independently selected from: hydrogen and C_{1-6} alkyl and wherein R^8 and R^9 may together form a 5- or 6-membered heterocyclic group containing one or more heteroatoms, selected independently from N, O and S;

~~R^{10} is selected from hydrogen and C_{1-6} alkyl;~~

~~R^{11} is selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkylCN, C_{0-6} alkylaryl, C_{2-6} alkylOR⁸,~~

~~C_{1-6} alkyl(CO)NR⁶R⁷, C_{1-6} alkyl(SO₂)R⁶, C_{1-6} alkyl(SO₂)NR⁶R⁷, C_{0-6} alkylheteroaryl,~~

~~C_{0-6} alkyl C_{3-6} heterocyclic group and C_{1-6} alkylNR⁶R⁷; and wherein any C_{0-6} alkylaryl and~~

~~C_{0-6} alkylheteroaryl may be substituted by one or more group Z; and wherein any~~

~~C_{0-6} alkyl C_{3-6} heterocyclic group may be substituted by one or more group Y;~~

~~Z is selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, OCF₃ and CF₃;~~

~~Y is selected from: oxo, C_{2-6} alkylOR⁸, C_{1-6} alkyl, C_{0-6} alkylaryl, C_{0-6} alkylheteroaryl, OR⁸ and C_{2-6} alkylNR⁸R⁹;~~

~~m is 0, 1, 2, 3 or 4 1;~~

~~n is 0, 1, 2, 3 or 4 1;~~

~~as a free base or a salt, or a tautomer thereof.~~

35. (cancelled).

36. (previously presented) A compound according to claim 34, wherein P is pyridine.

Claims 37 - 41 (cancelled).

42.(currently amended) A compound selected from:

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-6-carbonitrile hydrochloride;~~

~~6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-morpholin-4-ylethyl)nicotinamide hydrochloride;~~

~~6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)nicotinamide hydrochloride;~~

~~6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-(dimethylamino)ethyl)-N-methylnicotinamide hydrochloride;~~

~~6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride;~~

~~2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;~~

~~3-[5-({4-[2-(Dipropylamino)ethyl]piperazin-1-yl} sulfonyl)pyridin-2-yl]-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;~~

~~2-Hydroxy-3-(5-{[4-(2-morpholin-4-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;~~

~~2-Hydroxy-3-(5-{[4-(2-pyrrolidin-1-ylethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride;~~

~~2-Hydroxy-3-(5-{[4-(2-methoxyethyl)piperazin-1-yl]sulfonyl}pyridin-2-yl)-1*H*-indole-6-carbonitrile hydrochloride[[:]], or~~

~~2-Hydroxy-*N*-(3-methoxypropyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~*N*-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-*N*-(2-methoxybenzyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-N-[4-(trifluoromethoxy)benzyl]-1H-indole-5-carboxamide hydrochloride;~~

~~3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-N-(2-thienylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-N-(pyridin-2-ylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-N-(tetrahydrofuran-2-ylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~N-Benzyl-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-N-propyl-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-N-(2-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-N-(4-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-(pyridin-3-ylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-(pyridin-4-ylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-(pyridin-2-ylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-N-[2-(methylsulfonyl)ethyl]-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~3-(5-Cyanopyridin-2-yl)-2-hydroxy-N-{2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl}-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-sulfonamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-6-carboxamide hydrochloride;~~

~~3-[5-({4-[2-(Dimethylamino)ethyl]piperazin-1-yl)sulfonyl}pyridin-2-yl]-2-hydroxy-1H-indole-6-carbonitrile hydrochloride;~~

~~2-Hydroxy-N-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-1H-indole-5-carboxamide hydrochloride;
N-(2-Cyanoethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-N-[2-(1H-imidazol-4-yl)ethyl]-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~N-Benzyl-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-propyl-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-N-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~3-(5-Cyanopyridin-2-yl)-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-N-methyl-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~

~~6-Bromo-2-hydroxy-N-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~6-Bromo-2-hydroxy-N-isopropyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~6-Bromo-2-hydroxy-N-(2-methoxyethyl)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(tetrahydrofuran-2-ylmethyl)-1H-indole-5-carboxamide hydrochloride;~~
~~6-Bromo-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(2-pyrrolidin-1-ylethyl)-1H-indole-5-carboxamide hydrochloride;~~
~~N-[3-(Dimethylamino)propyl]-2-hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-N-(2-methoxyethyl)-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-pyridin-3-yl-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-N-(2-methoxybenzylamide)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-N-(3-methoxybenzylamide)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-N-(tetrahydro-2H-pyran-4-yl)-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-N-(4-methoxybenzylamide)-3-[5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~N-(Cyanomethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~N-(2-Furylmethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1H-indole-5-carboxamide hydrochloride;~~
~~2-Hydroxy-3-[5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride;~~
~~2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride;~~
~~2-Hydroxy-3-[5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl]-1H-indole-6-carbonitrile hydrochloride;~~
~~2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1H-indole-6-carbonitrile hydrochloride;~~

~~3-{6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl}-2-hydroxy-1H-indole-6-carbonitrile hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxylic acid hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-[3-(2-oxopyrrolidin-1-yl)propyl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-(2-thienylmethyl)-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-[2-(2-thienyl)ethyl]-1H-indole-5-carboxamide hydrochloride;~~

~~N-[2-(Acetylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~N-(2-Cyanoethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~N-(Cyanomethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carboxamide hydrochloride;~~

~~2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1H-indole-5-carboxylic acid carbamoylmethylamide hydrochloride;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-N-[2-(methylsulfonyl)ethyl]-1H-indole-5-carboxamide hydrochloride;~~

~~Methyl 3-fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-5-carboxylate hydrochloride;~~

~~3-(5-Diethylaminomethyl-pyridin-2-yl)-2-hydroxy-1H-indole-5-carboxylic acid-(2-methanesulfonyl-ethyl)-amide hydrochloride;~~

~~as a free base or another salt than hydrochloride, or a tautomer thereof;~~

~~2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1H-indole-5-carbonitrile;~~

~~3-(4-Cyanopyridin-2-yl)-2-hydroxy-N-(2-methoxyethyl)-1H-indole-5-carboxamide;~~

~~2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1H-indole-5-carboxylic acid (2-carbamoylethyl)amide;~~

~~2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1H-indole-5-carboxylic acid methyl ester;~~

~~2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1H-indole-5-carboxylic acid (thiophen-2-ylmethyl)-amide dihydrochloride;~~

~~2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1H-indole-5-carboxylic acid benzylamide dihydrochloride;~~

~~as a free base or a salt, or a tautomer thereof, or a free base of any of foregoing hydrochloride or a pharmaceutically acceptable salt of any said free base.~~

Claims 43 and 44 (cancelled)

45. (previously presented) A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound according to claim 34 in association with pharmaceutically acceptable carriers or diluents.

46. (cancelled)

47. (currently amended) A method of prevention and/or treatment of conditions associated with glycogen synthase kinase-3, comprising administering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia [[or Ib]] as defined in claim 34.

48. (currently amended) A method of prevention and/or treatment of a human or animal suffering from dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica, by administering to such a mammal, a therapeutically effective amount of a compound of formula Ia [[or Ib]] as defined in claim 34.


49. (previously presented) The method according to claim 48, wherein the prevention and/or treatment is for Alzheimer's Disease.

50. (currently amended) A method of prevention and/or treatment of a human or animal suffering from amyotrophic lateral sclerosis, corticobasal degeneration, Down syndrome, Huntington's Disease, postencephalic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, ~~contraceptive medication~~, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders, by administering to such a mammal, a therapeutically effective amount of a compound of formula Ia [[or Ib]] as defined in claim 34.

51. (currently amended) A method of prevention and/or treatment of a human or animal suffering from predemented states, Mild Cognitive Impairment, Age-Associated Memory Impairment, Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia, by administering to such a mammal, a therapeutically effective amount of a compound of formula Ia [[or Ib]] as defined in claim 34.


52. (currently amended) A method of prevention and/or treatment of a human or animal suffering from bone-related disorders, by administering to such a mammal, a therapeutically effective amount of a compound of formula Ia as defined in claim 34.

53. (currently amended) A process for the preparation of a compound of formula Ia according to claim 34, wherein P, R¹, R² and R³, m and n, unless otherwise specified, are as defined in claim 34, comprising reacting a compound of formula A, wherein L¹ is a leaving group, with a compound of formula D to form a compound of formula Ia;



said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

54. (currently amended) A process for the preparation of a compound of formula Ia according to claim 34, wherein R¹, R² and R³ and m, [[is]] are unless otherwise specified as defined in claim 34, and halo is halogen, unless otherwise specified, comprising: reacting a compound of formula B with a compound of formula D to form a compound of formula Ia;



said reaction being carried out in an appropriate solvent at a temperature between +10 °C and +150 °C.

Claims 55 - 59 (cancelled).

60. (new) A compound selected from:

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)carbonyl]pyridin-2-yl}-1H-indole-6-carbonitrile hydrochloride;

6-(6-Cyano-2-hydroxy-1H-indol-3-yl)-N-(2-morpholin-4-ylethyl)nicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-methyl-*N*-(2-pyrrolidin-1-ylethyl)nicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-(dimethylamino)ethyl)-*N*-methylnicotinamide hydrochloride;

6-(6-Cyano-2-hydroxy-1*H*-indol-3-yl)-*N*-(2-pyrrolidin-1-ylethyl)pyridine-3-sulfonamide hydrochloride;

2-Hydroxy-3-[5-(piperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Acetylamino)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxybenzyl)-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethyl)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[2-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-[4-(trifluoromethoxy)benzyl]-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

3-{5-[(Diethylamino)methyl]pyridin-2-yl}-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

N-Benzyl-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-*N*-propyl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxyphenyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-3-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-4-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(pyridin-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(methylsulfonyl)ethyl]-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-{2-[(4-methylpiperazin-1-yl)sulfonyl]ethyl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-sulfonamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-6-carboxamide hydrochloride;

3-[5-(4-[2-(Dimethylamino)ethyl]piperazin-1-yl)sulfonyl]pyridin-2-yl]-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-(5-nitropyridin-2-yl)-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Cyanoethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-[2-(1*H*-imidazol-4-yl)ethyl]-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-Benzyl-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-propyl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Dimethylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

3-(5-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-methyl-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-methyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-isopropyl-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-*N*-(2-methoxyethyl)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(tetrahydrofuran-2-ylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

6-Bromo-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-pyrrolidin-1-ylethyl)-1*H*-indole-5-carboxamide hydrochloride;

N-[3-(Dimethylamino)propyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxyethyl)-3-[5-(morpholin-4-ylsulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-pyridin-3-yl-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(2-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(3-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(tetrahydro-2*H*-pyran-4-yl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-*N*-(4-methoxybenzylamide)-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(Cyanomethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Furylmethyl)-2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[5-(piperidin-1-ylmethyl)pyridin-2-yl]-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(3-oxopiperazin-1-yl)methyl]pyridin-2-yl}-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-[6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]-1*H*-indole-6-carbonitrile hydrochloride;

3-{6-[2-(Diisopropylamino)ethoxy]pyrimidin-4-yl}-2-hydroxy-1*H*-indole-6-carbonitrile hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxylic acid hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[3-(2-oxopyrrolidin-1-yl)propyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-(2-thienylmethyl)-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-oxoimidazolidin-1-yl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(2-thienyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Acetylamino)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(2-Cyanoethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-[2-(Aminosulfonyl)ethyl]-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

N-(Cyanomethyl)-2-hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carboxamide hydrochloride;

2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid carbamoylmethylamide hydrochloride;

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-*N*-[2-(methylsulfonyl)ethyl]-1*H*-indole-5-carboxamide hydrochloride;

Methyl 3-fluoro-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]-2-oxoindoline-5-carboxylate hydrochloride;

3-(5-Diethylaminomethyl-pyridin-2-yl)-2-hydroxy-1*H*-indole-5-carboxylic acid (2-methanesulfonyl-ethyl)-amide hydrochloride;

2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid (thiophen-2-ylmethyl)-amide dihydrochloride, or

2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid benzylamide dihydrochloride;

or a free base of any foregoing hydrochloride, or a tautomer thereof, or a pharmaceutically acceptable salt of any said free base.

61. (new) A compound selected from:

2-Hydroxy-3-{5-[(4-methylpiperazin-1-yl)sulfonyl]pyridin-2-yl}-1*H*-indole-5-carbonitrile;

3-(4-Cyanopyridin-2-yl)-2-hydroxy-*N*-(2-methoxyethyl)-1*H*-indole-5-carboxamide;
2-Hydroxy-3-[5-(4-methylpiperazine-1-sulfonyl)pyridin-2-yl]-1*H*-indole-5-carboxylic acid (2-carbamoylethyl)amide;
2-Hydroxy-3-[5-(4-methyl-piperazin-1-ylmethyl)-pyridin-2-yl]-1*H*-indole-5-carboxylic acid methyl ester;
or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

62. (new) A pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of a compound according to claim 60 or 61 in association with a pharmaceutically acceptable carrier or diluent.

63. (new) A method of preventing or treating conditions associated with the action of glycogen synthase kinase-3, comprising administering to a subject in need of such prevention or treatment, a therapeutically effective amount of a compound according to Claim 60 or 61.

64. (new) A method according to claim 63 for preventing or treating dementia, Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia Parkinson's Type, Parkinson dementia complex of Guam, HIV dementia, diseases with associated neurofibrillar tangle pathologies and dementia pugilistica.

65. (new) A method according to claim 64, for preventing or treating Alzheimer's Disease.

66. (new) A method according to claim 63 for preventing or treating of a subject suffering from amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's Disease, postencephalatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, hair loss, Type I and Type II diabetes, diabetic neuropathy and diabetes related disorders.

67. (new) A method according to claim 63 for preventing or treating a subject suffering from a predemented state, Mild Cognitive Impairment, Age-Associated Memory Impairment,

Age-Related Cognitive Decline, Cognitive Impairment No Dementia, mild cognitive decline, mild neurocognitive decline, Late-Life Forgetfulness, memory impairment and cognitive impairment, vascular dementia, dementia with Lewy bodies, Frontotemporal dementia and androgenetic alopecia.

68. (new) A method according to claim 63 for preventing or treating a subject suffering from a bone-related disorder.